New pediatric formula for Chagas disease treatment developed in Brazil

NewsGuard 100/100 Score

"A new pediatric formulation developed in Brazil holds out hope for a cure for over 90 percent of newborn babies infected with Chagas disease, a parasitic infection endemic in 21 Latin American countries, where it kills more people every year than malaria," Inter Press Service reports. "The new pediatric dosage form of benznidazole, which has just been approved for registration by Brazil's National Health Surveillance Agency (ANVISA), was developed by the Pernambuco State Pharmaceutical Laboratory (LAFEPE) with the support of the Drugs for Neglected Diseases initiative (DNDi)," according to IPS.

Instead of trying to calculate pediatric doses by breaking up adult-sized pills, "[t]he new formulation, called LAFEPE Benznidazole 12.5 mg, in contrast, is easy and safe to use," IPS notes, adding, "Administering precise doses will minimize the risks of involuntarily giving too much or too little medication, and will avoid treatment interruptions" (Frayssinet, 12/8).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    New monoclonal antibody vaccine slashes malaria risk in children